Walvax Biotechnology to Issue A-Shares, Changing Control to Tengyun Xinwo

Today's market saw significant developments, particularly in the biotechnology and technology sectors. Notably, Walvax Biotechnology Co., Ltd. (300142) announced plans to issue A-shares to raise up to 2.203 billion RMB, which will result in a change of control to Tengyun Xinwo. This move is subject to shareholder approval and regulatory review.

Deals & Restructuring

• Walvax Biotechnology Co., Ltd. (300142): Plans to issue A-shares to Tengyun Xinwo, changing control and raising funds for working capital.
• Aike Co., Ltd. (300889): Proposes to acquire assets through share issuance and cash payments, raising supporting funds from up to 35 investors, subject to regulatory approval.
• ST Cuihua Co., Ltd. (002731): Under investigation for failing to disclose periodic reports; faces delisting risk if reports are not submitted within two months.
• TP-Link Software Co., Ltd. (300996): Shareholders of Pulin Software Co., Ltd. agreed to transfer a 19.07% stake to Beijing Minglue Zhaohui Technology, resulting in a change of control.
• *ST Xinyuan Co., Ltd. (300472): Progress on pre-restructuring matters, including court decisions and interim management appointments.

Regulatory & Governance

• Guangdong Shenling Environmental Systems Co., Ltd. (301018): Received supplementary legal opinions regarding its application for issuing convertible bonds.
• *ST Dali Co., Ltd. (002214): Announced the revocation of its delisting risk warning and will resume trading on August 5, 2026.

Other Notable Developments

• Xunyou Technology Co., Ltd. (300467): Reported a change in equity following a judicial auction, with new shareholders becoming the largest stakeholders.
• Xintian Technology Co., Ltd. (300615): Announced abnormal stock trading fluctuations due to a pending change in controlling shareholder.
• Hubei Dinglong Co., Ltd. (300054): Approved a share repurchase plan to maintain company value, with an investment of up to 200 million RMB.
• Rijiu Optoelectronics Co., Ltd. (003015): Plans to issue A-shares to raise up to 800 million RMB for a production project.
• Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702): Announced that its subsidiary has been selected for the 12th national centralized drug procurement, expected to boost sales.

Investors are advised to monitor these developments closely, as they may significantly impact company valuations and market dynamics.